Hepatorenal syndrome refers to functional kidney failure that may occur in patients suffering from cirrhosis (advanced liver disease) with ascites (fluid accumulation in the abdominal cavity).

AUSTIN, Texas -- Hepatorenal syndrome (HRS) type 1 patients showed clinically meaningful responses to terlipressin (Terlivaz) under an alternative definition of treatment success, according to a ...

Discover top medications for 'treating Hepatorenal Syndrome'? This page compiles essential information on generic and brand-name drugs specifically used for Hepatorenal Syndrome treatment.Here, you ...

Hepatorenal syndrome (HRS), a feared complication of advanced cirrhosis, is characterized by functional renal failure, secondary to renal vasoconstriction in the absence of underlying kidney pathology ...

Credit: Getty Images. Terlivaz is a vasopressin analogue selective for V1 receptors. The Food and Drug Administration (FDA) has approved Terlivaz ® (terlipressin) injection to improve kidney function ...

Hepatorenal syndrome is defined as renal failure in patients with advanced liver disease liver cirrhosis, ascites and liver failure in the absence of existing kidney disease or structural kidney ...

The US Food and Drug Administration's (FDA's) Cardiovascular and Renal Drugs Advisory Committee narrowly recommended, by an 8-7 vote, that the agency grant marketing approval to terlipressin for the ...

PHENURONE (phenylacetylurea) is a new anticonvulsant drug reported to be of value in psychomotor epilepsy. The control of psychomotor seizures has always been a difficult problem, but with the advent ...

New York, July 25, 2023 (GLOBE NEWSWIRE) -- Reportlinker.com announces the release of the report "Hepatorenal Syndrome Treatment Global Market Report 2023" - https ...

Major companies such as Noorik Biopharmaceuticals, Cumberland Pharmaceuticals, BioVie, and others are developing potential drug candidates to improve the Hepatorenal Syndrome treatment scenario.

STAINES-UPON-THAMES, United Kingdom, June 23, 2017 /PRNewswire/ -- Mallinckrodt plc (NYSE: MNK), a leading global specialty pharmaceutical company, today announced new retrospective, claims-based ...